Ellagic acid supplementation in patients with non-alcoholic fatty liver disease

Assessment of the Ellagic acid supplementation effect on lipid profile, liver enzymes, oxidative stress status and inflammatory factors in patients with non-alcoholic fatty liver disease: double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141025019669N21

Enrollment

Registered

2022-01-23

Start date

2022-01-21

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver disease. Other specified inflammatory liver diseases

Interventions

Intervention 1: Intervention group: Ellagic acid, a capsule 180 mg per daily for two months, Manufacturer: Supplement Spot. Intervention 2: Control group: A daily placebo capsule containing wheat flou

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 18-55 years old patient with non-alcoholic fatty liver, confirmation of non-alcoholic fatty liver with liver ultrasound Having a body mass index of less than 30 A consent signed by the patient.

Exclusion criteria

Exclusion criteria: Pregnancy and lactation Infectious disease, inflammatory disease, Cushing's syndrome, adrenal gland tumor, hypothyroidism, diabetes, and cancer. Taking antioxidant supplements in the last three months Taking medication in the last three months including glucocorticoids drugs, lipid-lowering drugs, and weight-loss drugs.

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Insulin. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Insulin resistance. Timepoint: Before the intervention and after the intervention. Method of measurement: Using the formula.;Total antioxidant capacity. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Malondialdehyde. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Lipid profile. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Liver enzymes. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Inflammatory factors. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Adiponectin hormone. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.	—

Measure

Time frame

Fasting blood sugar. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Insulin. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Insulin resistance. Timepoint: Before the intervention and after the intervention. Method of measurement: Using the formula.;Total antioxidant capacity. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Malondialdehyde. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Lipid profile. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Liver enzymes. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Inflammatory factors. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Adiponectin hormone. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Khadem Haghighian

Qazvin University of Medical Sciences

khademnut@yahoo.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026